Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma

Our previous phase I/II trial of pegylated liposomal doxorubicin (PLD), low-dose dexamethasone, and lenalidomide in patients with relapsed and refractory myeloma showed an overall response rate of 75%, with 29% achieving ≥VGPR. Here, we investigated this combination (PLD 30 or 40 mg/m(2) intravenous...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Am J Hematol
Main Authors: Baz, Rachid C., Shain, Kenneth H., Hussein, Mohamad A., Lee, Ji-Hyun, Sullivan, Daniel M., FinleyOliver, Elizabeth, Nardelli, Lisa A., Nodzon, Lisa A., Zhao, Xiuhua, Ochoa-Bayona, Jose Leonel, Nishihori, Taiga, Dalton, William S., Alsina, Melissa
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4522918/
https://ncbi.nlm.nih.gov/pubmed/24030918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23587
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki